 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5960616263646566676869...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - Oct 22, 2015
P4, N=12, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema (clinicaltrials.gov) - Oct 16, 2015
P3, N=180, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - Oct 15, 2015
P4, N=1044, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=3500 --> 1044
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Oct 13, 2015
P3, N=674, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=3500 --> 1044 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jul 2015
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (clinicaltrials.gov) - Oct 9, 2015
P3, N=357, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jul 2015 Active, not recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Oct 7, 2015
P3, N=455, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (clinicaltrials.gov) - Oct 6, 2015
P4, N=100, Recruiting, Sponsor: Nagoya City University
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Mar 2018
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Monotherapy: PROTEUS: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (clinicaltrials.gov) - Oct 1, 2015
P2/3, N=94, Active, not recruiting, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Trial primary completion date: Sep 2016 --> Mar 2018 Recruiting --> Active, not recruiting
- | PF 4634817 / Pfizer
Trial termination: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema (clinicaltrials.gov) - Sep 30, 2015
P2, N=212, Terminated, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Terminated
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Sep 30, 2015
P2, N=0, Withdrawn, Sponsor: Starr Muscle
Recruiting --> Terminated N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Sep 2015
- || acrizanib (LHA510) / Novartis
Trial primary completion date: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 28, 2015
P2, N=60, Recruiting, Sponsor: Alcon, a Novartis Company
N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Sep 2015 Trial primary completion date: Nov 2015 --> Apr 2016
- Rayoqta (abicipar pegol) / Molecular Partners
Trial primary completion date: A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 24, 2015
P2, N=25, Recruiting, Sponsor: Allergan
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SwapTwo: Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (clinicaltrials.gov) - Sep 24, 2015
P4, N=20, Not yet recruiting, Sponsor: Rishi Singh
- ||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial primary completion date: ARI2: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Sep 22, 2015
P3, N=90, Active, not recruiting, Sponsor: Centre Hospitalier Intercommunal Creteil
Trial primary completion date: Aug 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Dec 2015
- |||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial completion, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Sep 17, 2015
P2, N=158, Completed, Sponsor: Lpath, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Dec 2015 Active, not recruiting --> Completed
- |||| razuprotafib subcutaneous (AKB-9778 SC) / Aadi Biosci, EyePoint Pharma
Trial completion, Monotherapy: The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Sep 8, 2015
P2, N=144, Completed, Sponsor: Aerpio Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sozinibercept (OPT-302) / Opthea
New P1 trial, Combination therapy: Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis (clinicaltrials.gov) - Sep 8, 2015
P1, N=50, Recruiting, Sponsor: Opthea Pty Ltd.
- Izervay (avacincaptad pegol intravitreal solution) / Astellas
Enrollment closed: A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) - Sep 4, 2015
P2, N=5, Active, not recruiting, Sponsor: Ophthotech Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: Kagawa University
Recruiting --> Active, not recruiting Initiation date: Jan 2015 --> Sep 2015
- |||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: LADDER: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 2, 2015
P2, N=220, Recruiting, Sponsor: Genentech, Inc.
Initiation date: Jan 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates (clinicaltrials.gov) - Aug 31, 2015
P1/2, N=30, Recruiting, Sponsor: South Coast Retina Center; Carson, McBeath, Boswell, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Safety and Efficacy of Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Aug 28, 2015
P1/2, N=30, Active, not recruiting, Sponsor: Justis Ehlers
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| LMG324 / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Aug 27, 2015
P1/2, N=106, Recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Aug 26, 2015
P3, N=283, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Camellia: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Aug 26, 2015
P3, N=252, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=120, Recruiting, Sponsor: King's College Hospital NHS Trust
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Dec 2015
- | DS-7080a / Daiichi Sankyo
New P1 trial: Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) - Aug 21, 2015
P1, N=45, Recruiting, Sponsor: Daiichi Sankyo Inc.
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Retinal Sensitivity in BRVO After Anti-VEGF Therapy (clinicaltrials.gov) - Aug 19, 2015
P4, N=50, Recruiting, Sponsor: Fukushima Medical University
- | Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Aug 17, 2015
P2/3, N=24, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: May 2015 --> Dec 2015
- |||| Stivarga (regorafenib) / Bayer
Trial completion, Enrollment change, Trial primary completion date: DREAM: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Aug 17, 2015
P2a, N=52, Completed, Sponsor: Bayer
Trial primary completion date: May 2015 --> Dec 2015 Recruiting --> Completed | N=350 --> 52 | Trial primary completion date: Apr 2016 --> May 2015
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment change, Trial withdrawal: Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Aug 14, 2015
P4, N=0, Withdrawn, Sponsor: Federal University of S
Recruiting --> Completed | N=350 --> 52 | Trial primary completion date: Apr 2016 --> May 2015 N=10 --> 0 | Not yet recruiting --> Withdrawn
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: PEARL: Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas (clinicaltrials.gov) - Aug 13, 2015
P4, N=60, Not yet recruiting, Sponsor: PD. Dr. med. Armin Wolf
- |||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients (clinicaltrials.gov) - Aug 11, 2015
P2/3, N=80, Recruiting, Sponsor: East Florida Eye Institute
N=10 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: ERASER: Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab (clinicaltrials.gov) - Aug 6, 2015
P2/3, N=60, Recruiting, Sponsor: California Retina Consultants
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Dec 2016
- |||||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment open: SEQUOIA: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Aug 4, 2015
P3, N=900, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- |||||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment open: CDER: A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Aug 4, 2015
P3, N=900, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jul 30, 2015
P2, N=20, Recruiting, Sponsor: Ohr Pharmaceutical Inc.
- ||||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: LADDER: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jul 29, 2015
P2, N=220, Not yet recruiting, Sponsor: Genentech, Inc.
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study (clinicaltrials.gov) - Jul 29, 2015
P2, N=66, Not yet recruiting, Sponsor: University of Nebraska
- || Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial primary completion date: LUMINOUS: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (clinicaltrials.gov) - Jul 22, 2015
P=N/A, N=26146, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2016
- |||| Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: A Study of Abicipar Pegol in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jul 14, 2015
P2, N=151, Completed, Sponsor: Allergan
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2016 Active, not recruiting --> Completed
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: SEIRA: Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (clinicaltrials.gov) - Jul 9, 2015
P1, N=0, Withdrawn, Sponsor: Vitreous -Retina- Macula Consultants of New York
Active, not recruiting --> Completed N=10 --> 0
- |||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Combination therapy, Monotherapy: To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema (clinicaltrials.gov) - Jul 3, 2015
P4, N=60, Recruiting, Sponsor: The University of Hong Kong
N=10 --> 0 Not yet recruiting --> Recruiting
- ||||| Vabysmo (faricimab-svoa) / Roche
New P2 trial: AVENUE: A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 30, 2015
P2, N=271, Recruiting, Sponsor: Hoffmann-La Roche
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Trial initiation date: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=225, Not yet recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Jun 2015 --> Sep 2015
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion (clinicaltrials.gov) - Jun 23, 2015
P4, N=30, Recruiting, Sponsor: Nagoya City University
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New trial: Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent (clinicaltrials.gov) - Jun 17, 2015
P=N/A, N=70, Completed, Sponsor: Prince of Songkla University
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: aiRTo-PDR: 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial (clinicaltrials.gov) - Jun 17, 2015
P3, N=200, Recruiting, Sponsor: JUNYAN ZHANG
Initiation date: Jun 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jun 15, 2015
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Mar 2017
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie
New P4 trial: DIME: Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (clinicaltrials.gov) - Jun 15, 2015
P4, N=40, Recruiting, Sponsor: California Retina Consultants